Trial of platelet-derived growth factor antagonist, trapidil, in accelerated nephrotoxic nephritis in the rabbit.
The platelet-derived growth factor (PDGF) antagonist, trapidil, which also blocks the thromboxane and/or PG-endoperoxide receptor and is an inhibitor of thromboxane synthetase, was administered during rabbit accelerated nephrotoxic nephritis; the clinical and histological evolution was studied as well as urinary immunoreactive thromboxane (i-TXB2) and immunoreactive prostaglandin E2 (i-PGE2) excretion. Although the dose we used has been shown to be effective in vivo, and it inhibited the urinary i-TXB2 excretion on days 5 and 10, it neither inhibited the enhanced production of i-TXB2 on day 1, nor prevented the glomerular influx of monocytes on days 5 and 10. All clinical and histological data tend to be worse rather than better in trapidil-treated animals on days 5 and 10.
D000818:Animals; D015232:Dinoprostone; D005260:Female; D007678:Kidney Glomerulus / Q000473:pathology; D009000:Monocytes / Q000473:pathology; D009393:Nephritis / Q000188:drug therapy* / Q000473:pathology / Q000652:urine; D010982:Platelet-Derived Growth Factor / Q000037:antagonists & inhibitors*; D011458:Prostaglandins E / Q000652:urine; D011743:Pyrimidines / Q000627:therapeutic use*; D011817:Rabbits; D013929:Thromboxane B2 / Q000652:urine; D014192:Trapidil / Q000627:therapeutic use*
D010982:Platelet-Derived Growth Factor; D011458:Prostaglandins E; D011743:Pyrimidines; D013929:Thromboxane B2; D014192:Trapidil; D015232:Dinoprostone